false 0001279704 0001279704 2024-11-15 2024-11-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): November 15, 2024

 

 

Cellectar Biosciences, Inc.

(Exact name of Registrant as Specified in its Charter)

 

 

Delaware  1-36598  04-3321804
(State or other jurisdiction
of incorporation)		  (Commission
File Number)		  (IRS Employer
Identification No.)

 

100 Campus Drive, Florham Park, NJ, 07932

(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (608) 441-8120

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)		   Name of each exchange
on which registered
Common Stock, par value $0.00001 per share   CLRB   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01. Other Events.

 

On October 29, 2024, Cellectar Biosciences, Inc. (the “Company”) filed an amended Annual Report on Form 10-K/A for the fiscal year ended December 31, 2023 (the “Form 10-K/A”) with the Securities and Exchange Commission (the “SEC”). Due to an inadvertent omission, the consent of the Company’s independent registered public accounting firm dated October 29, 2024 and filed as Exhibit 23.1 to the Form 10-K/A did not include a reference to the Company’s following registration statements on Form S-1 (File Nos. 333-208638, 333-214310, 333-225675, 333-231888, 333-238132, and 333-268554), Form S-1 MEF (File Nos. 333-226374 and 333-238892), and Form S-3 (File Nos. 333-208189, 333-252309, 333-274880 and 333-279731). The correct consent of the Company’s independent registered public accounting firm dated November 15, 2024 (the “Revised Consent”) is attached as Exhibit 23.1 to this Current Report on Form 8-K and is hereby filed with the SEC. The Revised Consent does not change any previously reported financial results or other disclosure contained in the Form 10-K.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits

 

Number   Title
23.1   Consent of Independent Registered Public Accounting Firm
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CELLECTAR BIOSCIENCES, INC.
   
   
Date: November 15, 2024 By:

/s/ Chad J. Kolean 

  Name: Chad J. Kolean
  Title: Chief Financial Officer

 

 

 

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We consent to the incorporation by reference in Registration Statement Nos. 333-208638, 333-214310, 333-225675, 333-231888, 333-238132, and 333-268554 on Form S-1, Registration Statement Nos. 333-226374 and 333-238892 on Form S-1 MEF, Registration Statement Nos. 333-208189, 333-252309, 333-274880 and 333-279371 on Form S-3, and Registration Statement Nos. 333-164398, 333-195255, 333-221469, 333-233460, and 333-266594 on Form S-8 of our report dated October 29, 2024, relating to the financial statements of Cellectar Biosciences, Inc. appearing in this Annual Report on Form 10-K for the year ended December 31, 2023.

 

/s/ Deloitte & Touche LLP

 

Morristown, New Jersey
November 15, 2024

 

 

 

v3.24.3
Cover
Nov. 15, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 15, 2024
Entity File Number 1-36598
Entity Registrant Name Cellectar Biosciences, Inc.
Entity Central Index Key 0001279704
Entity Tax Identification Number 04-3321804
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 100 Campus Drive
Entity Address, City or Town Florham Park
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07932
City Area Code 608
Local Phone Number 441-8120
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.00001 per share
Trading Symbol CLRB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Cellectar Biosciences (NASDAQ:CLRB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Cellectar Biosciences.
Cellectar Biosciences (NASDAQ:CLRB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Cellectar Biosciences.